Pre-Approval Access to Amivantamab in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations who have Failed Platinum-Based Chemotherapy

Brief description of study

The purpose of this Expanded Access Program (EAP) is for patients with metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations (Exon20ins), and whose disease has progressed during or after current standard of care platinum-based chemotherapy. Eligible patients will receive the investigational drug Amivantamab, a fully-human, bispecific IgG1 antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptors. The study drug is investigational which means that the Food and Drug Administration (FDA) has not approved the drug for this use.


Clinical Study Identifier: s21-00053
ClinicalTrials.gov Identifier: NCT04599712
Principal Investigator: Joshua K Sabari.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.